Standard form for notification of major holdings To view click here

ImmuPharma PLC (LSE:IMM), (“ImmuPharma”, the Group or the “Company”), the specialist drug discovery and development company, is pleased to announce its unaudited interim results for the six months ended 30 June 2025 (the “Period”). Key Highlights (including post Period review) Financials For the period ended 30 June 2025, the Group reported a loss of £1.8…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that five of the six resolutions (Resolutions 1 – 5 inclusive) were duly passed by shareholders, while the special resolution (which required approval of 75% of votes cast to pass), was not approved. Details…

TR-1: Standard form for notification of major holdings from Lanstead To download form Click here

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting (“AGM”) has today been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2024 has also been posted to shareholders today. These documents will be available shortly, in electronic form,…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its Final Results for the twelve months ended 31 December 2024 (the “Period”). Key Highlights (including post Period review) Financials Loss for the Period of £2.5m (2023: £2.9m) Research and development expenses of £1.2m (2023: £2.0m) Administrative…

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company, is pleased to announce that the Company has agreed – by means of a Deed of Variation – with Incanthera plc (“Incanthera”), that warrants issued to the Company on 26 February 2020 (“Warrants”), in conjunction with Incanthera’s IPO onto the Aquis Exchange (“AQSE”), are…

Further opportunities to present recent insights into the MOA* of the P140 technology platform ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CEO of the R&D subsidiary ImmuPharma Biotech will be attending the Bio-Europe Spring Conference from 17-19 March 2025,…

ImmuPharma PLC (LSE:IMM), a leading specialist in peptide based drug discovery and development, announces a significant milestone in evidencing the unique mechanism of action (“MOA”) of its P140 autoimmune technology platform. Importantly, these new discoveries announced today, in respect to the MOA of P140, highlight that: P140 has a unique MOA: The results provide direct…

TR-1: Standard form for notification of major holdings from Lanstead To download form click here